IMWG consensus criteria for response and minimal residual disease in myeloma
This paper, produced by an expert panel of the International Myeloma Working Group (IMWG) reviews the assessment of disease response and endpoints for clinical trials, and provides updated response categories of minimal residual disease negativity.
Over the past decade, the treatment landscape for multiple myeloma has evolved significantly, largely due to the introduction of various new and effective drug classes that have markedly improved both response rates and the depth of response in patients.
Traditionally, response criteria in multiple myeloma relied on serum and urine assessments of monoclonal proteins, as well as bone marrow evaluations, which have been recognised as relatively insensitive. With the advent of innovative treatment strategies leading to higher rates of complete response, there is a pressing need to establish new response categories capable of identifying deeper responses than those conventionally classified as complete response.
Recent efforts have concentrated on detecting residual tumour cells within the bone marrow through advanced techniques such as flow cytometry and gene sequencing. Additionally, sensitive imaging modalities can help identify the presence of residual disease outside the bone marrow. By integrating these novel methods, the IMWG has introduced new response categories for minimal residual disease negativity, which can be evaluated alongside imaging-based assessments for the absence of extramedullary disease. This approach aims to facilitate uniform reporting standards both within clinical trials and in broader clinical practice.
Use Case
Type
Source
Content Collection
You might also like
IMWG immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
Step into the forefront of myeloma treatment with this latest publication from the International Myeloma Working Group immunotherapy committee.
IMWG GuidelineBSH/UKMS good practice paper on Diagnosis and management of smouldering myeloma
Explore the latest guidelines for Smouldering Myeloma care in the British Society for Haematology Good Practice Paper.
BSH GuidelineNICE guidelines on Spinal metastases and metastatic spinal cord compression [NG234]
This NICE guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC).
NICE GuidelineIMWG recommendations on the management of multiple myeloma-related renal impairment
The IMWG outline updates to clinical practice guidance for the management of multiple myeloma-related renal impairment.
IMWG GuidelineIMWG consensus guidelines and recommendations for infection prevention in myeloma
Infection poses a significant risk to patients with multiple myeloma, contributing to high rates of morbidity and mortality. This consensus statement from the International Myeloma Society outlines essential guidelines for infection prevention
IMWG GuidelineBSH/UKMS guidelines on the Diagnosis, investigation, and initial treatment of myeloma
These new guidelines, produced by the British Society for Haematology (BSH) and the UK Myeloma Society (UKMS), provide healthcare professionals with guidance on the anti-myeloma management of patients with newly diagnosed myeloma.
IMWG recommendations for the treatment of multiple myeloma-related bone disease
This guideline, authored by an interdisciplinary panel of experts in myeloma and myeloma bone disease, reviews the current evidence and offers management recommendations for myeloma-related bone disease.
IMWG GuidelineNICE guideline on Acute kidney injury: prevention, detection and management [NG148]
This NICE guideline provides recommendations for non-specialists for the identification and referral guidance for children and adults who present with symptoms or risk factors of acute kidney injury.
NICE GuidelineIMWG consensus recommendations on imaging in monoclonal plasma cell disorders
The IMWG present recommendations on imaging both in clinical practice and in the trial setting to help standardise the best imaging methods to use as myeloma patients progress through different disease stages.
IMWG GuidelineMY-RADS guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma
As whole-body MRI is listed in NICE guidance as the recommended first line imaging in patients with suspected myeloma, this paper outlines a clinical protocol: the Myeloma Response Assessment and Diagnosis System (MY-RADS), for its use and interpretation.
Other Guideline
